Ann: Appendix 4C - Quarterly, page-2

$30mil still in the bank and this...
The FDA program is open only to products that fulfil a strict set of qualifying criteria that demonstrate the product’s novelty and its potential to treat a serious or life-threatening disease. Designation represents a compelling milestone and is a strong endorsement of Botanix’s data. The Company will continue to work with the FDA to progress its ‘fast-track’ status application this quarter. In addition, the Company continues to actively explore opportunities for its synthetic cannabidiol and its cannabinoid analogue assets in other secondary infections and across different routes of administration. This is inclusive of assessing opportunities to expand its pipeline of therapeutics that are responsive to both pandemic associated and resistant bacterial threats.